Clinical Trials
2 trialsNCT05070104 2023-09-13
CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
Cornerstone Pharmaceuticals
Phase 1 Withdrawn
NCT00741403 2016-12-29
A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies
Cornerstone Pharmaceuticals
Phase 1 Completed